Published in Diabetes on April 01, 1997
Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol (2000) 1.76
PPARs and the cardiovascular system. Antioxid Redox Signal (2009) 1.28
Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol (2009) 1.10
Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. Br J Pharmacol (1999) 1.07
Correlation between changes of blood pressure with insulin resistance in type 2 diabetes mellitus with 4 weeks of pioglitazone therapy. Int J Diabetes Dev Ctries (2008) 1.01
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovasc Diabetol (2008) 0.99
Effects of long-term pioglitazone treatment on peripheral and central markers of aging. PLoS One (2010) 0.90
Troglitazone and pioglitazone attenuate agonist-dependent Ca2+ mobilization and cell proliferation in vascular smooth muscle cells. Br J Pharmacol (1999) 0.86
Effects of rosiglitazone on altered electrical left ventricular papillary muscle activities of diabetic rat. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.80
Enhanced inhibition of L-type calcium currents by troglitazone in streptozotocin-induced diabetic rat cardiac ventricular myocytes. Br J Pharmacol (2002) 0.80
Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation (1999) 8.04
Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA (1996) 4.03
Diabetes mellitus and hypertension. Hypertension (1992) 1.93
Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab (2001) 1.93
Altered platelet calcium metabolism as an early predictor of increased peripheral vascular resistance and preeclampsia in urban black women. N Engl J Med (1990) 1.80
Diabetes mellitus: a disease of abnormal cellular calcium metabolism? Am J Med (1994) 1.74
Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol (1999) 1.61
Bisphosphonates and atherosclerosis: why? Lupus (2005) 1.57
Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab (2002) 1.47
Plasma norepinephrine responses to posture and isometric exercise increase with age in the absence of obesity. J Gerontol (1983) 1.46
Erythrocyte cation metabolism in preeclampsia. Am J Obstet Gynecol (1989) 1.44
Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. Am J Cardiol (1996) 1.41
A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med (1990) 1.35
Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med (2000) 1.27
Metoclopramide stimulates prolactin secretion in man. J Clin Endocrinol Metab (1976) 1.18
17 beta-Estradiol attenuates voltage-dependent Ca2+ currents in A7r5 vascular smooth muscle cell line. Am J Physiol (1994) 1.16
Reduced contractile response to insulin and IGF-I in ventricular myocytes from genetically obese Zucker rats. Am J Physiol Heart Circ Physiol (2000) 1.10
Role of the sympathetic nervous system in blood pressure maintenance in obesity. J Clin Endocrinol Metab (1982) 1.09
Cost effectiveness of 24-hour ambulatory blood pressure monitoring in evaluation and treatment of essential hypertension. Am J Hypertens (1994) 1.06
Downregulation of K(+) channel genes expression in type I diabetic cardiomyopathy. Biochem Biophys Res Commun (2001) 1.04
Enumeration of waterborne Escherichia coli with petrifilm plates: comparison to standard methods. J Environ Qual (2003) 1.04
Enhanced 24-hour norepinephrine and renin secretion in young patients with essential hypertension: relation with the circadian pattern of arterial blood pressure. Am J Cardiol (1985) 1.03
Acute airway obstruction due to a benign cervical goiter. Otolaryngol Head Neck Surg (1987) 1.02
Diabetes mellitus and diabetes-associated vascular disease. Trends Endocrinol Metab (2001) 1.00
Ambulatory blood pressure monitoring in a nonacademic setting. Effects of age and sex. Am J Hypertens (1992) 0.99
High sacrectomy for locally recurrent rectal cancer: Can long-term survival be achieved? J Surg Oncol (2010) 0.99
Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension (1994) 0.99
Clinical review 91: Female sex hormones and cardiovascular disease in women. J Clin Endocrinol Metab (1997) 0.98
Altered inotropic response to IGF-I in diabetic rat heart: influence of intracellular Ca2+ and NO. Am J Physiol (1998) 0.97
Impairment of cardiopulmonary baroreflex after cardiac transplantation in humans. Circulation (1987) 0.97
Salt sensitivity and systemic hypertension in the elderly. Am J Cardiol (1988) 0.95
Insulin attenuates vasopressin-induced calcium transients and a voltage-dependent calcium response in rat vascular smooth muscle cells. J Clin Invest (1991) 0.95
Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia. Am J Med (1991) 0.95
Hyperpigmentation, vitiligo, and Addison's disease. Cutis (1985) 0.93
Metabolism of exogenous human chorionic gonadotrophin in men. J Endocrinol (1979) 0.93
Salt sensitivity in blacks. Salt intake and natriuretic substances. Hypertension (1988) 0.93
Leydig cell tumor induced hypercalcemia in the Fischer rat: morphometric and histochemical evidence for a humoral factor that activates osteoclasts. Am J Pathol (1982) 0.90
Tamoxifen (estrogen antagonist) inhibits voltage-gated calcium current and contractility in vascular smooth muscle from rats. J Pharmacol Exp Ther (1996) 0.89
Cardiovascular disease in the diabetic woman. J Clin Endocrinol Metab (1999) 0.89
Dopaminergic mediation of the natriuretic response to volume expansion. J Lab Clin Med (1985) 0.89
Hypertension symposium: newer topics on normal and abnormal blood pressure regulatory mechanisms. West J Med (1983) 0.89
Relative androgenicity, blood pressure levels, and cardiovascular risk factors in young healthy women. Am J Hypertens (1995) 0.88
Blood pressure and hormone changes associated with weight reduction in the obese. Hypertension (1982) 0.88
Circadian variation in plasma dopamine levels in man. J Endocrinol Invest (1984) 0.88
Influence of age on contractile response to insulin-like growth factor 1 in ventricular myocytes from spontaneously hypertensive rats. Hypertension (1999) 0.88
Pathophysiology of male hypogonadism associated with endogenous hyperestrogenism. Evidence for dual defects in the gonadal axis. N Engl J Med (1985) 0.88
Adrenal function following coronary bypass surgery. Am Heart J (1985) 0.87
Insulin potentiates platelet-derived growth factor action in vascular smooth muscle cells. Endocrinology (1998) 0.87
Effects of metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rat vascular smooth muscle. Endocrinology (1996) 0.87
Effects of vitamin E and glutathione on glucose metabolism: role of magnesium. Hypertension (1999) 0.87
Insulin resistance, carbohydrate metabolism, and hypertension. Am J Hypertens (1991) 0.86
Aplysia egg-laying hormone increases excitatory input into a retractor muscle of the buccal mass. Brain Res (1982) 0.86
Gender differences in vascular compliance in young, healthy subjects assessed by pulse contour analysis. J Clin Hypertens (Greenwich) (2001) 0.86
Dopaminergic modulation of aldosterone secretion in man is unaffected by glucocorticoids and angiotensin blockade. J Clin Endocrinol Metab (1981) 0.86
Inhibition of Rho protein stimulates iNOS expression in rat vascular smooth muscle cells. Am J Physiol Heart Circ Physiol (2000) 0.86
Metformin but not glyburide prevents high glucose-induced abnormalities in relaxation and intracellular Ca2+ transients in adult rat ventricular myocytes. Diabetes (1999) 0.86
Induction of vascular endothelial growth factor release by transcutaneous frequency modulated neural stimulation in diabetic polyneuropathy. J Endocrinol Invest (2007) 0.86
Calcium and protein kinase C mediate high-glucose-induced inhibition of inducible nitric oxide synthase in vascular smooth muscle cells. Hypertension (1998) 0.85
Comparison of metoclopramide with other dynamic tests of prolactin secretion. J Clin Endocrinol Metab (1976) 0.85
Effects of high calcium intake on blood pressure and calcium metabolism in young SHR. Hypertension (1984) 0.85
Hyperinsulinemia, insulin resistance, and hyperglycemia: contributing factors in the pathogenesis of hypertension and atherosclerosis. Am J Hypertens (1993) 0.85
Role of cellular calcium metabolism in abnormal glucose metabolism and diabetic hypertension. Am J Med (1989) 0.85
Altered dopaminergic modulation of sympathetic nervous system activity in idiopathic edema. J Endocrinol Invest (1984) 0.85
Parathyroid carcinoma: diagnosis and management. Eur J Surg Oncol (2001) 0.85
Insulin-like growth factor I diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology (1996) 0.85
Reductions in plasma catecholamines and blood pressure during weight loss in obese subjects. Acta Endocrinol (Copenh) (1983) 0.85
Relation of cellular potassium to other mineral ions in hypertension and diabetes. Hypertension (2001) 0.85
Troglitazone attenuates high-glucose-induced abnormalities in relaxation and intracellular calcium in rat ventricular myocytes. Diabetes (1996) 0.84
Dissociation of 24-hour catecholamine levels from blood pressure in older men. Hypertension (1986) 0.84
Hypertension in the elderly. Am J Med (1987) 0.84
Vascular insulin abnormalities, hypertension, and accelerated atherosclerosis. Am J Kidney Dis (1993) 0.84
Reductions in total and extracellular water associated with calcium-induced natriuresis and the antihypertensive effect of calcium in blacks. Am J Hypertens (1988) 0.84
Using zebra mussels to monitor Escherichia coli in environmental waters. J Environ Qual (2001) 0.84
An update on perioperative management of diabetes. Arch Intern Med (1999) 0.84
Dopaminergic control of prolactin and blood pressure: altered control in essential hypertension. Hypertension (1982) 0.83
Magnesium and aging. Curr Pharm Des (2010) 0.83
Behavioral state changes induced in Pleurobranchaea and Aplysia by serotonin. Behav Neural Biol (1982) 0.83
Dopaminergic control of plasma catecholamine and aldosterone responses to acute stimuli in normal man. J Clin Endocrinol Metab (1980) 0.83
Dopaminergic modulation of renin release. Clin Exp Hypertens (1981) 0.83
Magnesium responsiveness to insulin and insulin-like growth factor I in erythrocytes from normotensive and hypertensive subjects. J Clin Endocrinol Metab (1998) 0.83
Dopaminergic regulation of natriuretic response to acute volume expansion in dogs. Clin Sci (Lond) (1985) 0.83
Growth hormone and prolactin secretion in Huntington's disease. Life Sci (1979) 0.83
In vivo and in vitro induction of germinal vesicle breakdown in a freshwater bivalve, the zebra mussel Dreissena polymorpha (Pallas). J Exp Zool (1994) 0.83
Insulin like growth factor 1 increases vascular smooth muscle nitric oxide production. Life Sci (1997) 0.82